Bio-Techne Corporation

Healthcare · Biotechnology

Overall research band Mixed

Quality Weak

Valuation Very weak

Balance sheet Above average

Market confirmation Exceptional

One-minute company read

What this report can tell you now

What the company does

Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for research, diagnostics, and bioprocessing markets worldwide. Operating through its Protein Sciences and Diagnostics and Spatial Biology segments, the company provides biological reagents such as cytokines, growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies, as well as proteomic analytical tools including automated western blot and multiplexed ELISA instruments. Its Diagnostics and Genomics segment offers diagnostic products like controls, calibrators, diagnostic assays, exosome-based molecular diagnostic assays, tissue-based in-situ hybridization assays, and genetic and oncology kits for research and clinical applications. Customers include organizations in life science research, diagnostics, and clinical laboratories. Bio-Techne generates revenue by selling these products and services globally.

The current research profile is Turnaround Candidate, with strong market confirmation. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC5.2%Model input; read with the evidence status and period context.

Operating margin12.7%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years7.0%Model input; read with the evidence status and period context.

FCF margin22.3%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.